Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

Stock Information for Alector Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Alector Inc.

Alector to Participate in Upcoming Healthcare Conferences
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
Alector Provides Executive Leadership Update
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
Alector to Participate in Upcoming Healthcare Conferences
Alector Provides Executive Leadership Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.